首页> 美国卫生研究院文献>The Oncologist >Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

【2h】

Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

机译：一线吉非替尼治疗的EGFR突变阳性晚期非小细胞肺癌患者总体生存预后因素的真实数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background.This study aimed to identify independent prognostic factors for overall survival (OS) of patients with advanced non‐small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation and receiving gefitinib as first‐line treatment in real‐world practice.

机译：背景：本研究旨在确定具有激活表皮生长因子受体（EGFR）突变并接受吉非替尼作为一线治疗的晚期非小细胞肺癌（NSCLC）患者的总生存（OS）的独立预后因素-世界惯例。

著录项

期刊名称 The Oncologist
作者
Zong‐Han Yao; Wei‐Yu Liao; *; Chao‐Chi Ho; Kuan‐Yu Chen; Jin‐Yuan Shih; Jin‐Shing Chen; Zhong‐Zhe Lin; Chia‐Chi Lin; James Chih‐Hsin Yang; Chong‐Jen Yu;
展开▼
作者单位

展开▼
年(卷),期 2017(22),9
年度 2017
页码 1075–1083
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Non‐small cell lung cancer Gefitinib Prognostic factors Chronic hepatitis C Intracranial progression;

机译：非小细胞肺癌;吉非替尼;预后因素;慢性丙型肝炎;颅内进展;

相似文献

外文文献
中文文献
专利

1. Reala??World Data on Prognostic Factors for Overall Survival in EGFR Mutationa??Positive Advanced Nona??Small Cell Lung Cancer Patients Treated with Firsta??Line Gefitinib [J] . Zonga??Han Yao, Weia??Yu Liao, Chaoa??Chi Ho, The oncologist . 2017,第9期

机译：Reala-EGFR突变总体生存预后因素的世界数据-阳性一线吉非替尼治疗的晚期晚期Nona-小细胞肺癌患者
2. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib [J] . Yao Zong-Han, Liao Wei-Yu, Ho Chao-Chi, The oncologist . 2017,第9期

机译：eGFR突变阳性晚期非小细胞肺癌患者总生存率的实证数据
3. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [J] . Paz-Ares L., Tan E. -H., OByrne K., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第2期

机译：AFATINIB与吉替尼患者患有EGFR突变阳性高级非小细胞肺癌的患者：IIB阶段LUX-LUNG 7试验的总体存活数据
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Treating Very Large Non-Small Cell Lung Cancers: A Survival Analysis using National Cancer Databases [D] . Moreno, Amy Catherine 2014

机译：治疗非常大的非小细胞肺癌：使用国家癌症数据库的生存分析
6. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [O] . L. Paz-Ares, E.-H. Tan, K. O’Byrne, -1

机译：阿法替尼vs吉非替尼治疗EGFR突变阳性的晚期非小细胞肺癌患者：IIb LUX-Lung 7期试验的总体生存数据
7. Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib [O] . Zong‐Han Yao, Wei‐Yu Liao, Chao‐Chi Ho, 2017

机译：关于EGFR突变阳性晚期非小细胞肺癌患者全面存活的预后因素的现实世界数据

Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

摘要

著录项

相似文献

相关主题

期刊订阅